Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.…
Earnings Beat May Change The Case For Aurinia Pharmaceuticals Stock
Aurinia Pharmaceuticals (NASDAQ: AUPH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 128 employees.
The shares were at 14.70 USD on 20 November 2026, down 5.4% over 52 weeks. Its 52-week range is 13.52 USD to 19.25 USD: the price is 23.6% below the high and 8.7% above the low.
At a market capitalisation of 1.97B USD, it trades at 6.4 times trailing earnings and 12.7 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 81% for AUPH.
Aurinia Pharmaceuticals reports return on equity of 49.4%, an operating margin of 51.6% and revenue up 13.9% year over year.
It holds more cash than debt, a net cash position of 427.86M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 18.50 USD is 25.9% above the current price. The next earnings report is expected on 1 March 2027.